<section-header><section-header><text>

HUMAN TERATOGENS – UPDATE 2010

LEWIS B. HOLMES, M.D.

Genetics Unit MassGeneral Hospital *for* Children Department of Pediatrics, Harvard Medical School

> E-mail: holmes.lewis@mgh.harvard.edu Tel: 617-726-1742; Fax: 617-724-1911

DEFINITION OF A TERATOGEN

An exposure in pregnancy that has a harmful fetal effect.

RECOGNIZED HUMAN TERATOGENS

- 1. DRUGS:
 - Ex. anticonvulsants methimazole retinoic acid (Accutane) warfarin
- 2. HEAVY METALS: Ex. lead mercury
- 3. RADIATION: cancer therapy; not diagnostic X-rays
- 4. MATERNAL CONDITIONS Ex. insulin-dependent diabetes, cigarette, smoking, alcohol abuse

- 5. INTRAUTERINE INFECTIONS Ex. toxoplasmosis rubella varicella
- 6. PROCEDURES Ex. CVS D & C ICSI amniocentesis
- 7. OTHER Ex. hypotension misoprostol heat

HUMAN TERATOGENS UPDATE - 2010

- **1. CHARACTERISTICS OF A HUMAN TERATOGEN**
- 2. INFORMATION SOURCES
- 3. MAJOR LIMITATIONS IN KNOWLEDGE
- 4. DIFFICULTIES IN COUNSELING


CHARACTERISTICS OF A HUMAN TERATOGEN


- **1.** An increase in the frequency of an abnormal fetal effect;
- A dose-response relationship; there is a threshold below which the exposure is not teratogenic;
- 3. Period of greatest sensitivity;
- Established mechanism of action, which often requires animal model;
- 5. The proposed teratogenicity must make sense biologically;
- 6. Identifying a genetically more susceptible group.

POTENTIAL FETAL EFFECTS

Spontaneous abortion Growth restriction Pattern of major and minor anomalies Major malformations only Stillbirth Abruptio placenta Cognitive dysfunction

Altered social behavior Cancer Maternal diabetes Alcohol Anticonvulsant drugs, Warfarin, retinoic acid Cigarette smoking Maternal diabetes Cocaine Retinoic acid, PCB phenobarbital, lead Diethylstilbestrol (DES)





EPIDEMIOLOGIC STUDIES: CASE-CONTROL

EX. Sodium valproate-exposed pregnancies showed increased risk of spina bifida:

Odds Ratio: 20.6 (p < 0.000001)

Ref: Robert E, Guibaud P: Lancet 2:937 and 1096, 1982.

PROBLEM: A case-control study focuses on only selected effects; does not describe the spectrum of fetal effects.

EPIDEMIOLOGIC STUDIES: COHORT STUDY

EX: Anticonvulsant drugs

Exposed and unexposed infants examined systematically to determine the spectrum of physical effects

> Midface and Digit Hypoplasia Major malformations Microcephaly Growth restriction

Ref: Holmes LB et al: N Engl J Med 344:1132-8, 2001

THE THRESHOLD DOSE CONCEPT

-- there is for some teratogens a level of exposure below which there is no harmful fetal effect.

Brent RL: Teratology 34:359-360, 1986

Gaylor DW et al: Teratology 38:389-391, 1988

Table 1.Teratogenic effects and their frequencies relative to the degree of
maternal hyperphenylalaninemia in offspring from untreated
maternal phenylketonuria and hyperphenylalaninemia

Offspring Abnormality	Ma	ternal Phenyla (µM)		
	>1200	1000-1200	600-1000	200-600
Mental Retardation	92%	73%	22%	21%
Microcephaly	73%	68%	35%	24%
Congenital heart disease	12%	15%	6%	0
Low birth weight	40%	52%	56%	13%

(from Lenke and Levy, '80)

^aTo convert to milligrams per deciliter (mg/dl), multiply by 0.0165

DOSE-RESPONSE RELATIONSHIP

Valproic acid: Omtzigt JGL et al: Neurol 42 (Suppl 5):119,92

	Infants with spina bifida (n=5)	Exposed, but normal (n=84)	
VPA conc. mg/l	73.4 ± 25	43.9 ± 21.6	p=.023
Peak dose admin.	650 ± 124	384 ± 19	p=.002

Also, see Mawer G et al: Seizure 11:512-18, 2002

	NONE	Light	Heavy	
Sample Size	<u>0</u> 64	<u>>0 to <16</u> 45	<u>≥16</u> 36	<u>p valu</u>
Mother's current Smoking (cig/d)	0.4	8.1	16.5	0.001
Family income (x\$1,000)	57.2		45.8	0.01
Child's age (yrs)	14.6	14.5	14.7	
General IQ	115 <u>+</u> 14.3	109.1 <u>+</u> 12.4	103.2 ± 11.8	0.001
Reading	114.	110.	107.	0.01
Spelling	107.	104.	102.	
Arithmetic	102		94.	

DOSE-RESPONSE RELATIONSHIP

EXAMPLE: ACCUTANE vs. RETIN-A

ACCUTANE, taken by mouth, increases fetal level of all-transretinoic acid; 35% rate of major malformations and high rate of mental retardation without malformations.

RETIN-A, applied topically, has little absorbed and is not teratogenic, i.e. no harmful fetal effect.

ACCUTANE (ISOTRETINOIN; 13-CIS-RETINOIC ACID)

35% Have Major Malformations

- Conotruncal Heart Defects
- Cranial Nerve Palsies
- Absence of Vermis of Cerebellum
- Moderate to Severe Mental Retardation

25% Of Children With No Malformations Are Mentally Retarded





TRETINOIN: TOPICAL EXPOSURE IN PREGNANCY (all trans retinoic acid)

CLINICAL STUDIES:

Exposed vs. controls showed no increased rate of malformations.

REFERENCES:

De Wals P et al: Paediat Perinat Epid 5:445-7, 1991 Johnson K et al: Teratology 49:375, 1994 Shapiro L et al: Lancet 350:1143-1144, 1997

TRETINOIN CREAM: PHARMACOKINETIC MODEL

"Topical application of tretinoin in human beings Results in an internal exposure that is four to six orders of magnitude <u>lower</u> than a minimally teratogenic dose"

Clewell III, HJ et al: A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:S77-S85, 1997.

PERIOD OF GREATEST SENSITIVITY:

KNOWN FOR FEW HUMAN TERATOGENS

Ex. THALIDOMIDE: days 20-34 postfertilization WARFARIN: weeks 4-7 (anticoagulant) METHOTREXATE: weeks 6-8 (chemotherapy)

IN GENERAL:

1st trimester: 2nd, 3rd trimester:

malformations IQ effect PROPOSED TERATOGENICITY MUST MAKE SENSE BIOLOGICALLY: ONE THAT DID NOT

Example: BENDECTIN (VITAMIN B6 AND ANTIHISTAMINE)

- SCIENTIFIC EVIDENCE LACKING
- DRUG RE-INTRODUCED IN CANADA

Brent RL: Reprod Toxicol 13:245-253, 1999.

CYP1A1 Mspl polymorphism:

Genotypes: AA homozygous wild type Aa heterozygous variant type aa homozygous variant type Phase I enzyme: metabolism of chemicals in cigarette smoke

GSTT1 gene, a major phase 2 enzyme:

(Glutathione-S-transferase: GST) Genotypes: AA: present Aa: present aa: deletion

	E SMOKING GENOTYPE:			· · · · · · · · · · · · · · · · · · ·	THER'S
ALL	<u>SMOKING</u> never continuous	BLACK -264 gms	<u>ף</u> .05	<u>WHITE</u> -309	<u>ף</u> .06
MOTHER'S GENOTYPE 1. CYPIAI Aa/aa (MSP1)	never continuous	+24 -475	.81 .007	+63 -467	.79 .05
2. GSTTI present	continuous	-61	.70	-291	.10
absent (deletion)	"	-594	.006	-579	.03

Wang X et al: JAMA 2002; 287:195-202. Chong Y-C et al: J Occ Env Med 2003; 45:392-498

HUMAN TERATOGENS: INFORMATION SOURCES

- Literature searches
 - ACOG Technical Bulletins
- Symposia
- Postgraduate courses
- Annual Meetings
 - Teratology Society
 - DW Smith Workshop
 - Soc Perinatal Epidem
- Books
- Computer based databases
 - TERIS, Reprotox, Shepard's Catalog
- OTIS and ENTIS

OTIS - Organization of Teratogen Information Systems		
Example:	Centers collaborate to identify exposed pregnancies and organize follow-up exams.	
Examples:	asthma medication leflunomide (Arava)	
Outcomes:	body and head size, dysmorphic features, major malformations	
	http://www.otispregnancy.org/	

HUMAN TERATOGENS: LIMITATIONS

- LACK OF KNOWLEDGE MOLECULAR BASIS
- - CELLULAR BASIS
 - EPIGENETIC EFFECTS
- NEED SYSTEMATIC STUDIES OF EFECTS ON LEARNING AND I.Q.
- NEED STUDIES OF AIRBORNE AND DERMAL EXPOSURS

HUMAN TERATOGENS: MECHANISMS OF ACTION

WARFARIN*: INHIBITION OF VITAMIN K REDUCTASE

PROPYLTHIOURACIL**: BLOCKS CONVERSION OF THYROXINE TO TRIIODOTHYRONINE

*Van Driel D et al: Teratology 66:127-140, 2002 **Rosenfeld H et al: Brit J Clin Pharm 68:609-617, 2009

HUMAN TERATOGENS: CELLULAR EFFECTS

WARFARIN:	Why is nose cartilage affected so dramatically?
VALPROATE:	Why does the effect on neural tube produce myelomeningocele and not anencephaly?
PHENYTOIN:	Why are effects primarily on distal phalanges of fingers, but not in the toes?

HUMAN TERATOGENS: EPIGENETIC EFFECTS?

One example is assisted reproductive technology (ART): 25% of infants with Angelman Syndrome* had imprinting defect with silencing of maternal UBE3A gene.

*Ludwig M: J Med Genet 42:289-291, 2005 Cox GF et al: Am J Hum Genet 71:162-164, 2002

ANTICONVULSANTS: EFFECTS ON INTELLIGENCE

ISSUES: AGE OF CHILD

TESTING INSTRUMENT

TESTING PARENTS


SELECTION OF MATCHED CONTROL

EFFECT OF CONFOUNDERS, e.g. SES

Domain	PB Effect	Significant p value (1-tailed)
Verbal Knowledge	Yes	0.035
Verbal Memory	No	
Perceptual Organization	Yes	0.054
Visual Memory	Yes	0.023
Distractibility	Yes	0.005
Drawing Ability	Yes	0.035
Motor Speed	No	

HUMAN TERATOGENS: COUNSELING ISSUES

- MISINFORMATION: Plague of PDR
- INCONCLUSIVE STUDIES: EXAMPLES Selective Serotonin Re-uptake Inhibitors (SSRI) Phthalates Bisphenol A Tumor necrosis factor-alpha antagonist
- FDA'S ADVERSE EVENT REPORTS: HAVE NOT HELPED TO IDENTIFY HUMAN TERATOGENS
- EFFECTS OF LITIGATION
- HORNS OF A DILEMMA



PHYSICIANS DESK REFERENCE (PDR)

- Section on risks in pregnancy designed to protect liability.
- Two systematic studies showed poor correlation between categories A, B, C, D and X with clinical data available.
- SEE: Friedman JM et al: Ob Gyn 75:594-599, 1990 Lo WY, Friedman JM: Ob Gyn 100:465-473, 2002 Public Affairs Comm (Teratology Society): Teratology 49:446-447, 1994. Kweder S: Teratology 63:270, 2001

MOST MEDICATIONS NOT STUDIED FOR FETAL EFFECTS

STUDY OF ALL DRUGS APPROVED BY FDA 1980-2000 468 DRUGS: 80% "RISK UNDETERMINED" USED ONLINE "TERIS" AS SOURCE

POOR CORRELATION OF TERIS RATINGS AND FDA DRUG CATEGORIES (A, B, C, D & X) FOR 163 DRUGS KAPPA STATISTIC = 0.08 ± 0.04

Lo WY, Friedman JM: Am J Ob Gyn 2002; 100:465-473.

SSRIs

- Celexa (citalopram)
- Lexapro (escitalopram)
- Luvox (fluvoxamine)
- Paxil (paroxetine)
- Prozac (fluoxetine)
- Zoloft (sertraline)

PAROXETINE HYDROCHLORIDE IS A SELECTIVE SEROTONIN-REUPTAKE INHIBITOR AND AN ANTIDEPRESSANT. METABOLIZED BY THE CYTOCHROME P-450 (CYP) 2D6 ISOENZYME. COMPLETELY ABSORBED FROM GI TRACT. ELIMINATION HALF-LIFE 21-24 HOURS.

SSRIs: ? FETAL EFFECTS

GSK Retrospective Study by Ingenix (ctr.gsk.co.uk/welcome.asp) Finding: Possible "signal" for heart defects, esp. ventricular septal defects, in spontaneous reports in GSK Bupropion Pregnancy Registry.

	Bupropion -	Other antidepressants*
	first trimester	first trimester
	<u>(n = 463)</u>	(n = 3,241)
trial septal defect (ASD)	0	4
oarctation	1	1
etralogy of Fallot	0	1
ransposition of great arteries	0	1
entricular septal defect (VSD)	6	18
otal (all defects)**	9	36

SSRIs AND HEART DEFECTS

Slone Birth Defects Study: Louik C et al: N Engl J Med 356:2675-2683, 2007.

	Paroxetine	<u>Fluoxetine</u>	<u>Sertraline</u>
Any heart defect	OR 1.4	0.9	1.5
	(0.2, 2.5)	(0.6, 1.5)	(0.9, 2.5)
Septal defects	0.8	1.2	2.0
	(0.3, 2.2)	(0.5, 2.2)	(1.2, 4.0)
RVOTD	3.3	1.0	2.0
	(1.3, 8.8)	(0.2, 3.4)	(0.6, 6.8)

No association with anencephaly, omphalocele or craniosynostosis

SSRIS AND HEART DEFECTS

CDC: National Birth Defects Prevention Study: Alwan S et al: N Engl J Med 356:2684-2692, 2007.

All heart defects, all SSRIs – no association

RVOTO: Paroxetine OR 2.5 (1.0, 6.0)

positive association with anencephaly, omphalocele craniosynostosis

SSRI: Questions about fetal effects

Evidence of dose-response relationships?

Any relevant animal model?

Biologic plausibility

ANY DRUG – SPECIFIC EFFECTS?

Any pattern of dysmorphic features or multiple anomalies?

Any evidence of over-representation of muscular VSDs or tiny ASDs?

HORMONALLY ACTIVE AGENTS: PHTHALATES

"PLASTICIZERS": PRENATAL EXPOSURE CORRELATES WITH GENITAL EFFECTS IN MALES – TESTIS FUNCTION AND ANOGENITAL DISTANCE

Swan SH et al: Environ Health Persp 81:1056-1061, '05. Salazar-Martinez E et al: Environmental Health 3:8-14, '04.

Measuring Anogenital Distance



TUMOR NECROSIS FACTOR ANTAGONIST (TNF-α): ? NEW TERATOGEN

1. Analysis of Adverse Event Reports at FDA: NOT HELPFUL

Carter JD et al: J Rheumatol 36:635-641, 2009

2. OTIS Findings promising ? Major teratogen

FDA: ADVERSE EVENT REPORTS


USE TO IDENTIFY HUMAN TERATOGENS

FALSE ALARMS:

TOPICAL TRETINOIN → HOLOPROSENCEPHALY
FRANZ ROSA
NO: De Wals et al: Paediat Perinat Epid 5:445-7, 1991.

- STATINS \rightarrow

Edison RJ, Muenke M: N Engl J Med 350:1379-82, 1991 NO: Petersen EE et al: AmJ Med Genet 146A:2701-5, 2008



PREGNANCY REGISTRIES:

COMPANY BASED:

- Antiretroviral Drugs in Pregnancy Registry:
- VARVAX Pregnancy Registry
- Lamotrigine Pregnancy Registry

HOSPITAL-BASED:

- Isotretinoin Pregnancy Registry
- National Transplant in Pregnancy Registry
- North American AED (antiepileptic drug) Pregnancy Registry

NEED: NATIONAL CENTER TO ADVISE

TERATOGEN COUNSELING: VALPROATE

Patient: 12 weeks GA, taking 1,500 mg/day

Issues: Misinformation ("Its just spina bifida. Take your folic acid and don't worry.")

> Risk for developmental delay: hard to quantify Risk for autism: unknown rate Prenatal screening: not much help Change medication: ?

"NEW" TERATOG	EN?
SULFONAMIDE: ASSOC	IATIONS
ANENCEPHALY : OR 3.	4 (95 CI : 1.3 – 8.8)
HLHS : OR 3.	2 (95 CI : 1.3 – 7.6)
COARCTATION OF AOR	TA: OR 3.2 (95 CI:1.3 – 5.6)
NITROFURANTOIN: ASS	OCIATIONS
ANOPHTHALMIA/MICRO	- : OR 3.7 (95 CI:1.1 – 12.2)
HLHS	: OR 4.2 (95 CI : 1.9 – 9.1)
CLEFT LIP/PALATE	: OR 2.1 (95 CI : 1.2 – 3.9)
METHOD: NBDPS – 13,155 MAL	FORMED; 4,941 CONTROLS
CRIDER KS ET AL: ARCH PEDIA	TR ADOL MED 163:978-985, 2009.

T.V. ADVERTISEMENT - BOSTON, 2007

ATTORNEY MARK

If you took Paxil while pregnant and had a child with a heart defect or pulmonary hypertension, call Attorney Mark ______ at 617-___-.

TERATOLOGY SOCIETY CHALLENGE

EDUCATE, EDUCATE, EDUCATE

Opportunities at annual meetings ? Updates on specific exposures ? Annual symposium

Send your students to Human Teratogens Course in Boston

	Hun	ADVERTISEMENT: nan Teratogens Postgraduate Course
	SUN	DAY, MAY 1 – TUESDAY, MAY 3, 2011 Massachusetts General Hospital
Fee:	\$575 \$325	Physicians Nurses, nurse midwives, genetic counselors Special arrangements available for students
To Register:	To Register: Harvard Med-CME http://cme.med.harvard.edu/courses/humanteratogens	
For Informatic	on call:	Rosanna Greco (Course Coordinator) Tel: 617-726-1742 or E-mail: Rgreco@partners.org

THE CHALLENGE

"The problem with communication ... is the illusion that it has been accomplished."

George Bernard Shaw